biote Corp. (NASDAQ:BTMD) Short Interest Update

biote Corp. (NASDAQ:BTMD) was the recipient of a large drop in short interest during the month of September. As of September 15th, there was short interest totalling 1,110,000 shares, a drop of 5.9% from the August 31st total of 1,180,000 shares. Based on an average daily trading volume, of 246,800 shares, the short-interest ratio is currently 4.5 days. Currently, 3.7% of the company’s stock are sold short.

Insider Buying and Selling at biote

In other news, CFO Robert Charles Peterson sold 11,376 shares of the business’s stock in a transaction that occurred on Tuesday, July 9th. The stock was sold at an average price of $7.57, for a total value of $86,116.32. Following the transaction, the chief financial officer now owns 32,874 shares in the company, valued at approximately $248,856.18. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 13.90% of the company’s stock.

Institutional Trading of biote

Large investors have recently bought and sold shares of the company. Bandera Partners LLC increased its holdings in biote by 7.5% in the 4th quarter. Bandera Partners LLC now owns 1,832,732 shares of the company’s stock worth $9,054,000 after acquiring an additional 127,410 shares during the last quarter. SW Investment Management LLC increased its stake in shares of biote by 3.5% in the fourth quarter. SW Investment Management LLC now owns 675,000 shares of the company’s stock worth $3,334,000 after purchasing an additional 22,651 shares in the last quarter. Sanders Morris Harris LLC bought a new stake in shares of biote in the second quarter valued at approximately $585,000. Bank of New York Mellon Corp lifted its stake in shares of biote by 59.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 94,318 shares of the company’s stock valued at $705,000 after buying an additional 34,999 shares in the last quarter. Finally, Bailard Inc. bought a new position in biote in the 2nd quarter worth approximately $146,000. 21.68% of the stock is owned by hedge funds and other institutional investors.

biote Trading Down 1.8 %

BTMD stock opened at $5.48 on Wednesday. biote has a 1-year low of $3.65 and a 1-year high of $8.44. The stock has a market cap of $339.96 million, a P/E ratio of 49.82 and a beta of 0.94. The stock’s fifty day simple moving average is $6.27 and its two-hundred day simple moving average is $6.40.

biote (NASDAQ:BTMD) last released its earnings results on Thursday, August 8th. The company reported $0.14 earnings per share for the quarter, beating analysts’ consensus estimates of $0.09 by $0.05. The firm had revenue of $49.17 million during the quarter, compared to the consensus estimate of $50.40 million. biote had a net margin of 3.67% and a negative return on equity of 20.92%. As a group, analysts forecast that biote will post 0.52 earnings per share for the current fiscal year.

About biote

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.